OVERVIEW

Community Practice Connections™: Medical Crossfire®: Leveraging the Lung Cancer Team in Stage III Non-Small Cell Lung Cancer (NSCLC) With Immuno-Oncology Strategies is organized by Physicians' Education Resource, LLC (PER).

Release Date: November 27, 2019
Expiration Date: November 27, 2020

Accreditation:
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
Community Practice Connections™: Medical Crossfire®: Leveraging the Lung Cancer Team in Stage III NSCLC With Immuno-Oncology Strategies consists of a series of interactive clinical vignettes, short video interviews with leading experts in lung cancer, and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes as well as questions commonly faced in the community oncology practice setting.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Describe the scientific underpinnings of tumor immunology and the scientific rationale for immune checkpoint inhibition in the management of early-stage and locally advanced NSCLC
• Apply clinical trial evidence to optimize the use of immune checkpoint inhibitors for the treatment of stage III NSCLC
• Evaluate evolving uses of biomarkers and how they have been investigated as methods to inform clinical decision making in the care of patients with NSCLC
• Discuss methods to proactively identify and mitigate the impact of immune-related adverse events in stage III NSCLC

Benefits of Participating:
• Learn about the rationale for using immunotherapy with multimodality approaches
• Discuss the role of biomarker testing in patients with unresectable stage III non–small cell lung cancer (NSCLC)
• Incorporate standard-of-care management for patients with unresectable stage III NSCLC
• See how experts manage immunotherapy-related adverse events